FDY.F SHANGHAI FUDAN H YC-,10

Healthcare Drug Manufacturers - Specialty & Generic Frankfurt Exchange
0.8221 EUR
Close of Nov 11, 2026
0.2340 0.3660
Market cap
EUR 280M
P/E
-
P/B
0.96x
ROE
-7.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is FDY.F undervalued?

Graham number

The Graham number of SHANGHAI FUDAN H YC-,10 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

SHANGHAI FUDAN H YC-,10 fundamental analysis

No fundamental analysis for SHANGHAI FUDAN H YC-,10 yet.

SHANGHAI FUDAN H YC-,10 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About SHANGHAI FUDAN H YC-,10

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technology drugs. The company was founded in 1996 and is based in Shanghai, the People'…

Full company profile